Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma

NCT06406634 is registered in ClinicalTrials.gov with Hunan Cancer Hospital as lead sponsor.

NCT NCT06406634
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06406634 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma
Lead sponsor
Hunan Cancer Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
May 15, 2024
Completion date
April 20, 2027
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma